Edition:
United States

Sarepta Therapeutics Inc (SRPT.OQ)

SRPT.OQ on NASDAQ Stock Exchange Global Select Market

45.17USD
4:00pm EDT
Change (% chg)

$-1.93 (-4.10%)
Prev Close
$47.10
Open
$46.97
Day's High
$46.97
Day's Low
$45.10
Volume
562,908
Avg. Vol
642,747
52-wk High
$63.73
52-wk Low
$26.26

Latest Key Developments (Source: Significant Developments)

Sarepta Therapeutics reports positive results in study
Wednesday, 6 Sep 2017 07:00am EDT 

Sept 6 (Reuters) - Sarepta Therapeutics Inc :Sarepta Therapeutics announces positive results in its study evaluating gene expression, dystrophin production, and dystrophin localization in patients with duchenne muscular dystrophy (DMD) amenable to skipping exon 53 treated with golodirsen (SRP-4053).Sarepta Therapeutics Inc - ‍study achieved statistical significance on all primary and secondary biological endpoints​.Sarepta Therapeutics Inc - ‍study also showed a statistically significant increase in dystrophin immunofluorescence as measured by immunohistochemistry​.  Full Article

Sarepta Therapeutics announces pricing of $325 mln public offering of common stock
Monday, 24 Jul 2017 08:03pm EDT 

July 24 (Reuters) - Sarepta Therapeutics Inc :Sarepta Therapeutics announces pricing of $325 million public offering of common stock.Sarepta Therapeutics - Priced underwritten public offering of an aggregate of 7.65 million shares of common stock at a price to public of $42.50 per share.  Full Article

Sarepta Therapeutics announces proposed $250 mln public offering of common stock
Monday, 24 Jul 2017 07:00am EDT 

July 24 (Reuters) - Sarepta Therapeutics Inc ::Sarepta Therapeutics announces proposed $250 million public offering of common stock.Sarepta - intends to use net proceeds from offering principally for continuation and initiation of further clinical trials.  Full Article

Sarepta Therapeutics announces Q2 revenue $35 million
Wednesday, 19 Jul 2017 04:01pm EDT 

July 19 (Reuters) - Sarepta Therapeutics Inc :Sarepta Therapeutics announces second quarter 2017 financial results and recent corporate developments.Q2 non-GAAP loss per share $0.46.Q2 revenue $35 million.Q2 revenue view $22.4 million -- Thomson Reuters I/B/E/S.Q2 earnings per share view $-0.91 -- Thomson Reuters I/B/E/S.Q2 GAAP loss per share $1.15.Sarepta Therapeutics Inc says increased revenue guidance range to $125 - $130 million for year.  Full Article

Sarepta Therapeutics and Clinigen launch managed access program
Wednesday, 19 Jul 2017 08:30am EDT 

July 19 (Reuters) - Sarepta Therapeutics Inc ::Sarepta Therapeutics and Clinigen launch a managed access program to treat patients with duchenne muscular dystrophy amenable to exon 51 skipping.Sarepta Therapeutics Inc - ‍Sarepta plans to expand program to include more countries over time​.Sarepta - program being launched in select countries within Europe, North America,South America for certain patients where eteplirsen not approved​.  Full Article

Sarepta and Biomarin report execution of global settlement
Tuesday, 18 Jul 2017 08:30am EDT 

July 18 (Reuters) - Sarepta Therapeutics Inc ::Sarepta Therapeutics and Biomarin Pharmaceutical Inc. Announce execution of a global settlement and a license agreement resolving exon skipping patent litigation.Sarepta Therapeutics Inc - ‍under terms of license and settlement agreements, Sarepta will make a one-time payment of $35 million to Biomarin​.Says ‍Sarepta will also pay royalties to Biomarin​.Sarepta- ‍Biomarin retains right to convert license to a co-exclusive right in event it decides to proceed with an exon-skipping therapy for dmd​.Sarepta Therapeutics- ‍Biomarin retains right to convert license to co-exclusive right in event it decides to proceed with exon-skipping therapy for DMD​.Sarepta Therapeutics - to make ‍additional regulatory, commercial milestone payments for exons 51, 45, 53, possibly on future exon-skipping products.Sarepta-‍effectiveness of agreements subject to closing conditions including execution of necessary approvals by Academisch Ziekenhuis Leiden by July 24​.  Full Article

Sarepta, Genethon announce research collaboration for DMD treatment
Wednesday, 21 Jun 2017 07:00am EDT 

June 21 (Reuters) - Sarepta Therapeutics Inc ::Sarepta Therapeutics and Genethon announce a gene therapy research collaboration for the treatment of Duchenne Muscular Dystrophy.Sarepta Therapeutics Inc - financial terms of collaboration have not been disclosed.Sarepta Therapeutics Inc - Sarepta has option to co-develop Genethon's micro-dystrophin program, which includes exclusive U.S. commercial rights.Sarepta Therapeutics Inc - under terms of collaboration, Genethon will be responsible for early development work.  Full Article

Paulson & Co Inc takes share stake in Amazon, Arconic - SEC filing
Monday, 15 May 2017 05:33pm EDT 

May 15 (Reuters) - Paulson & Co Inc : :Paulson & Co Inc takes share stake in Amazon of 5,500 shares - SEC filing.Paulson & Co Inc takes share stake of 983,300 shares in Arconic Inc.Paulson & Co Inc takes share stake of 78,101 shares in Sarepta Therapeutics Inc.Paulson & Co Inc ups share stake in Glaxosmithkline PLC by 40.2 percent to 415,100 Sponsored ADR.Paulson & Co Inc - Change in holdings are as of March 31, 2017 and compared with the previous quarter ended as of Dec 31, 2016.  Full Article

Summit Therapeutics says completes enrolment of PhaseOut DMD
Monday, 15 May 2017 07:00am EDT 

May 15 (Reuters) - Summit Therapeutics Plc :Summit completes enrolment of PhaseOut DMD, a phase 2 clinical trial of ezutromid in patients with dmd.Summit Therapeutics - with dosing of last patient in trial, co has triggered $22 million milestone payment.$22 million milestone payment is part of company's licence and collaboration agreement with Sarepta Therapeutics Inc.  Full Article

Sarepta Therapeutics says CEO Edward Kaye intends to resign
Thursday, 27 Apr 2017 05:19pm EDT 

April 27 (Reuters) - Sarepta Therapeutics Inc -:Sarepta Therapeutics Inc - on April 24, Edward M. Kaye president, chief executive officer informed board of his intention to resign - sec filing.Sarepta - CEO Edward M. Kaye informed board of intention to resign upon conclusion of current employment term on sept 20, or some other future date.Sarepta Therapeutics Inc - Kaye will continue to serve as a director following his resignation as president and chief executive officer.  Full Article

Sarepta's shares jump on new DMD drug's promising trial results

Sarepta Therapeutics Inc's shares surged on Wednesday after the results of a trial on its drug to treat a fatal muscle-wasting disease showed it had the potential to be more effective than the company's approved drug for the same disease.